By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors Graham, Philip B.; Silverman, I. Robert, filed on November 18, 2014, was made available online on March 19, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Concert Pharmac
Intercept intends to use the net proceeds of this offering to support the expansion of its clinical, regulatory, medical affairs and commercial infrastructure in the United States and Europe, the clinical development program for obeticholic acid in primary biliary cirrhosis, nonalcoholic steatohepatitis and primary sclerosing cholangitis, the...
MELBOURNE& SYDNEY, Australia Amneal Pharmaceuticals Pty Ltd and Actavis Australia Pty Ltd, a subsidiary of Actavis plc, today announced they have signed a binding letter of intent which provides that Amneal intends to acquire substantially all of Actavis in-country generic pharmaceuticals business for an agreed price, subject to completion o
The following information should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere in this report. We are an emerging pharmaceutical company engaged in the commercialization, licensing, and development of safe and effective non-prescription medicine and consumer care products to improve men's...
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced the pricing of an underwritten public offering of 1,200,000 shares of its common stock. A preliminary prospectus supplement relating to the...
UBS Investment Bank and Citigroup are acting as underwriters in the offering. A preliminary prospectus supplement relating to the shares of common stock sold in this offering was filed with the SEC on March 31, 2015. Copies of the final prospectus may be obtained from the offices of UBS Investment Bank c/o Prospectus Department, 1285 Avenue of the
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced that it is commencing an underwritten public offering of 1,200,000 shares of its common stock. Intercept intends to use the net proceeds of th
Our strategy is to bring new products to market by identifying optimal delivery mechanisms and/or alternative applications for FDA- approved active pharmaceutical ingredients, or APIs, and biological materials, while, in appropriate circumstances, reducing the time, cost and risk typically associated with new product development by taking advantage
The following discussion of results of operations and financial condition is based upon, and should be read in conjunction with, our consolidated financial statements and accompanying notes thereto, included elsewhere in this Annual Report. This discussion contains forward-looking statements. HealthWarehouse.com, Inc. is America's Trusted Online...
By a News Reporter-Staff News Editor at Pharma Business Week VANC Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter markets, is pleased to announce that the Company has received $2,000,000 in proceeds from the exercise of warrants. "This injection of capital will assist us in two key areas o
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Insert as second sentence after Reference underneath ella Important Safety Information paragraph: For Full Prescribing Information, please go to: http://pharma.afaxys.com/afaxys/assets/pdf/ella-FPI. pdf. The corrected release reads: AFAXYS PHARMACEUTICALS ANNOUNCES LAUNCH.
Boston Therapeutics, Inc., a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2014 and provided a corporate update. David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said
WASHINGTON, March 27 The U.S. Department of Health& Human Services published the following proposed rule in the Federal Register from the Food& Drug Administration:. A Proposed Rule by the Food and Drug Administration on 03/27/2015. Dates: The public hearing will be held on April 20 and 21, 2015, from 9 a.m. to 4 p.m. The meeting may be extended
Flamel Technologies today announced the results of a First-in-Man clinical study in healthy volunteers using its proprietary LiquiTime drug delivery platform applied to guaifenesin, a broadly used expectorant. The chosen formulation will be optimized and scaled up over the coming months and Flamel plans to perform a pivotal study in 2016. There
FDA is seeking participants for the public hearing and written comments from all interested parties, including, but not limited to, consumers, patients, caregivers, health care professionals, patient groups, and industry. FDA is seeking input on a number of specific questions, but is interested in any other pertinent information participants would
PHILADELPHIA, PA/ ACCESSWIRE/ March 27, 2015/ Olfactory Biosciences Corp is pleased to announce that its manufacturing partner FFS has Kosher Certification as well as an FDA approved facility. FFS has the superior technical expertise that is necessary to produce our products. Olfactory Biosciences uses a new innovative delivery system, the company'
Actavis reported that it has completed the acquisition of Allergan, Inc. in a cash and equity transaction valued at approximately $70.5 billion. "The combination of Actavis and Allergan creates an exceptional global pharmaceutical company and a leader in a new industry model- Growth Pharma," said Brent Saunders, CEO and President of Actavis.
The Food and Drug Administration says that it will hold a two-day meeting next month on regulations for homeopathic medicines, which have long occupied a place on the fringes of U.S. health care. According to a federal notice published online Thursday, the FDA will ask attendees whether there is data to "better assess the risks and benefits" of hom
As a 31 year prosecution veteran, the current elected Prosecutor for Cass County Michigan and the President of the Prosecuting Attorneys Association of Michigan it is an honor to appear before the Energy and Commerce Commission Chaired by Congressman Fred Upton, and more particularly, its Subcommittee on Oversight and Investigations chaired by...
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd invited university researchers with expertise in public policies and environmental protection as well as government health officials, to discuss the issue at a forum in Beijing on March 21. Many countries, including the United States and Japan, have regulations on expired drug disposal, and some h
Supplement Companies in focus today are Axxess Pharma, Inc., GNC Holdings, Inc., MusclePharm Corporation, Vitamin Shoppe, Inc.. Axxess Pharma, Inc., a specialty pharmaceutical and nutritional supplements company, through its wholly owned subsidiary, AllStar Health Brands Inc., holds an exclusive alliance to supply TapouT Muscle Recovery, Topical Pa
Fisher Wallace Laboratories today announced that its popular neurostimulation device, called the Fisher Wallace Stimulator , has been approved by New York City Health and Hospitals Corporation. New York City Health and Hospitals Corporation is comprised of eleven of New York City's largest hospitals, including Bellevue Hospital, Woodhull Hospit
Boston Therapeutics, Inc., affiliate in Hong Kong, Advance Pharmaceutical Company, Ltd., initiated enrollment of the first subjects in a clinical trial at The Chinese University of Hong Kong to evaluate the effects of SUGARDOWN who are pre-diabetic. David Platt, Ph.D., CEO of Boston Therapeutics, said, "We are moving forward in our key strategic
Moberg Pharma AB today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,987,330 for Moberg Pharma's market-leading product Kerasal Nail , an over-the-counter product for fungal nails. Based on this innovation, Moberg Pharma launched the second generation of its market leading product Kerasal Nail in the
Moberg Pharma AB today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,987,330 for Moberg Pharma's market-leading product Kerasal Nail? , an over-the-counter product for fungal nails. Based on this innovation, Moberg Pharma launched the second generation of its market leading product Kerasal Nail? in